pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
=== US food distribution from 1900 to 1960 === The United States' food distribution system has experienced major changes in the past hundred years. Food distribution primarily relied on small, local farms in the 1940s, but quickly grew to become a large business in the 1960s. Three economic advances that allowed for the growth in food distribution between 1910 and 1960 were the establishment of chain stores, retail cooperatives, and supermarkets.
=== Cellulose nanocrystals === Cellulose nanocrystals (CNCs), or nanocrystalline cellulose (NCC), are highly crystalline, rod-like nanoparticles. They are usually covered by negatively charged groups that render them colloidally stable in water. They are typically shorter than CNFs, with a typical length of 100 to 1000 nanometers.
High doses of nicotinic acid are also associated with a potential for adverse effects, most commonly a niacin flush reaction that is characterized by redness or flushing of the skin, sensations of heat, itching, and tingling. The nicotinamide vitamer of vitamin B3 does not exhibit the same therapeutic effect for treatment of hypercholesterolemia, but also does not cause a niacin flush reaction and is not associated with the same adverse effects as nicotinic acid.
Sources: en.wikipedia.org
Laidlaw left Valve in 2016. He said later that he had grown tired of the FPS genre and was "less interested in trying to solve the story problems inherent in a Half-Life style of narrative". In 2017, Laidlaw posted a short story titled "Epistle 3" on his website, describing it as "a snapshot of a dream I had many years ago". It features characters with names similar to Half-Life characters, such as Gertie Fremont for Gordon Freeman. Journalists interpreted the story as a synopsis of what could have been the plot for Episode Three, or for Borealis, another canceled project led by Laidlaw. Substituting the characters and locations with their Half-Life counterparts, "Epistle 3" has Gordon and Alyx travel to the Arctic to board the Borealis, a ship that travels erratically through time and space, where they confront alternative versions of themselves. They rig the Borealis to travel to the heart of the alien Combine empire and self-destruct. Before it explodes, the mysterious G-Man extracts Alyx and Gordon is rescued by the friendly Vortigaunt aliens. Walker denied that the story had been Valve's plan for Episode Three, and said that it was likely just one of many ideas by Laidlaw. In a 2023 interview, Laidlaw said it was not representative of Episode Three, as "all the real story development can only happen in the crucible of developing the game". He said he regretted publishing it, as it had created problems for his former colleagues at Valve, and that he had been "deranged" and "completely out of touch".
The isotopic compositions of ice cores from continental ice sheets and alpine glaciers have been developed as temperature proxies since the 1950s. Samuel Epstein was one of the first to show the applicability of this proxy by measuring oxygen isotopes in Antarctic snow, and also pointed out complications in the stable isotope-temperature correlation caused by the history of the air masses from which the snow formed. Ice cores in Greenland and Antarctica can be thousands of meters thick and record snow isotopic composition of the past few glacial-interglacial cycles. Ice cores can be dated by layer counting on the top and ice flow modeling at depth, with additional age constraints from volcanic ash. Cores from Greenland and Antarctica can be aligned in age at high-resolution by comparing globally well-mixed trace gas (e.g. CH4) concentrations in the air bubbles trapped in the cores. Some of the first ice core records from Greenland and Antarctica with age estimates go back to the last 105 years, and showed a depletion in δD and δ18O in the last ice age. The ice core record has since been extended to the last 800,000 years in Antarctica, and at least 250,000 years in Greenland. One of the best δD-based ice core temperature records is from the Vostok ice core in Antarctica, which goes back to 420,000 years. The δD-temperature (of the inversion layer where snow forms) conversion in east Antarctica based on modern spatial gradient of δD (9‰/°C) is ΔTI=(ΔδDice-8Δδ18Osw)/9, which takes into account variations in seawater isotopic composition caused by global ice volume changes.
==== Reliable prediction of T-cell epitopes ==== A novel input representation has been developed consisting of a combination of sparse encoding, Blosum encoding, and input derived from hidden Markov models. This method predicts T-cell epitopes for the genome of hepatitis C virus and discuss possible applications of the prediction method to guide the process of rational vaccine design.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.